NCT01010984已完成不适用
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Robert C. Martin6 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年9月最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 6
- 主要终点
- Incidence of Adverse Events
研究概览
简要总结
The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.
详细描述
In this study, trans-arterial chemoembolization will be used to deliver LC beads loaded with Doxorubicin directly into liver tumors resulting from malignant melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with unresectable, measurable disease defined as at least one lesion that can be accurately and serially measured per the modified RECIST and EASL criteria (2D/3D-EASL) or MRI (Extent of Necrosis)
- •Patients ≥ 18 years of age, > 35kg, of any race or sex, who have histological or radiological proof of melanoma to the liver
- •ECOG performance status < 3
- •Patient chooses to participate and has signed the informed consent document
- •Patients with unilobar disease who can be treated superselectively in a single session or patients with bilobar disease who can have both lobes able to be treated within 3 - 4 weeks in separate sessions
- •Patients with patent main portal vein
- •Ocular melanoma is allowed
- •Patients with clinically and radiologically stable brain metastasis from melanoma can be included
- •Patients with liver dominant disease (>50% overall tumor burden)
- •Prior systemic therapy for metastatic disease is allowed
- •Non-pregnant with an acceptable contraception in premenopausal women and fertile men
- •Hematological function: ANC ≥1.5 x 109/L, platelets ≥ 75 x 109/L, INR ≤1.3 (patients on therapeutic anticoagulants are not eligible)
- •Adequate renal function: Creatinine ≤2.0mg/dl and GFR >30
- •Adequate liver function: total bilirubin ≤ 2.5 mg/dl, ALT, AST ≤ 5 times ULN, albumin ≥ 2.5mg/dl
- •All toxic effects of prior therapy must have resolved to ≤ Grade 1 unless otherwise specified above
排除标准
- •Women who are pregnant or breast feeding
- •Patients eligible for curative treatment such as resection or radiofrequency ablation
- •Active bacterial, viral or fungal infection within 72 hours of study entry
- •Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 5 years prior to study entry
- •Contraindication to hepatic artery embolization procedures:
- •Severe peripheral vascular disease precluding catheterization
- •Large shunt as determined by the investigator (pretesting with TcMAA not required) at the time of first angiogram
- •Hepatofugal blood flow
- •Main portal vein occlusion (e.g. thrombus or tumor)
- •Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment.
- •Allergy to contrast media that cannot be managed with standard care (e.g. steroids), making magnetic resonance imaging (MRI) or computed tomography (CT) contraindicated
- •Advanced liver disease (> 80% liver replacement)
- •Other significant medical or surgical condition, or any medication or treatment that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation
- •Any contraindication for doxorubicin administration:
- •WBC <3000 cells/mm3
- •Neutrophils <1500 cells/mm3
- •Deficient cardiac function defined as a LVEF of <50% normal
研究组 & 干预措施
Transcatheter Arterial Chemoembolization
Experimental
TACE using LC beads loaded with Doxorubicin
干预措施: LC beads loaded with Doxorubicin (Device)
结局指标
主要结局
Incidence of Adverse Events
时间窗: Date of surgery through 2 years post procedure or until patient death
Adverse events were collected from all 20 subjects.
次要结局
- Percentage of Tumor Response(Percentage of tumor response assessed up to 1 year post treatment.)
研究者
Robert C. Martin
Professor University of Louisville
University of Louisville
研究点 (6)
Loading locations...
相似试验
已完成
4 期
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACEHepato Cellular CarcinomaNCT03706157University Hospital, Strasbourg, France10
已完成
1 期
Sorafenib With TACE to Treat Hepatocellular CarcinomaHepatocellular CarcinomaNCT00478374University of Bern21
已完成
2 期
Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid FibromatosisDesmoidDesmoid Fibromatosis of SkinDesmoid Neoplasm of Chest WallDesmoid Tumor Caused by Somatic MutationAggressive FibromatosesFibromatosis DesmoidDesmoid FibromatosisNCT03966742Rabin Medical Center8
招募中
2 期
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCCHepatocellular Carcinoma Non-resectableNCT06397235Second Affiliated Hospital of Guangzhou Medical University130
Unknown
1 期
TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma PatientsStage IV Melanoma Patients With Unresectable Liver MetastasesNCT01409733Heidelberg University20